A Review on the Therapeutic Targeting of the Gut Microbiome for the Mitigation of Type 2 Diabetes Mellitus

Review article

Abstract

Type 2 diabetes mellitus is a principal driver of global metabolic morbidity, dictated by complex interactions between genetic susceptibility and environmental pressures. Emerging paradigms identify the gastrointestinal microbiome as a critical metabolic regulator, acting as a virtual endocrine organ that influences systemic insulin sensitivity, energy harvest, and inflammatory tone. Dysbiosis, characterized by a depletion of butyrate-producing taxa and an expansion of pathobionts, compromises intestinal barrier integrity, leading to metabolic endotoxemia and chronic low-grade inflammation. This disruption alters key microbial-derived signaling molecules, specifically short-chain fatty acids and secondary bile acids, which subsequently impairs the activation of G-protein coupled receptors and farnesoid X receptors crucial for glucose homeostasis and incretin secretion. Therapeutic modulation of these metagenomic networks presents a viable strategy for metabolic normalization. Interventions utilizing target-specific probiotics, prebiotic substrates, synergistic synbiotics, and fecal microbiota transplantation display therapeutic efficacy in clinical and preclinical evaluations by restoring metabolic pathways and reducing systemic insulin resistance. Combining metagenomic profiling into clinical diagnostics facilitates personalized metabolic interventions, transitioning diabetes management from generalized glycemic control to precise, host-microbiome-aligned therapies. Optimizing clinical outcomes requires overcoming current limitations in microbial delivery systems, characterizing long-term safety, and standardizing therapeutic protocols to fully harness the endocrine potential of the gut microbiome